It relates to a topical composition comprising specific amounts of: a) a hyaluronic acid or a pharmaceutically or veterinary acceptable salt thereof, b) one or more adhesive agents, and c) a non-absorbable antibiotic; to delivery devices comprising it; and to its uses in medicine, in particular, in the treatment and/or prevention of mucosal lesions; in the prevention of postpolypectomy syndrome; as adjuvant therapy to mechanical treatments in gastrointestinal perforations, and as sealant treatment in surgical anastomoses and leaks or fistulas in gastrointestinal tract.

The present invention is directed to a hemostatic or tissue sealing material having (a) a peptide having a sequence SEQ ID NO: 1 or an amino acid analog sequence thereof, and (b) a scaffold for said peptide or amino acid analogue sequence. The scaffold is preferably hemostatic, such as a natural or genetically engineered absorbable polymer, a synthetic absorbable polymer, or combinations thereof. The natural or genetically engineered absorbable polymers can be selected from the group consisting of a protein, a polysaccharide, or combinations thereof.

A sterile, ready-to-use, flowable haemostatic composition comprises a soluble haemostatic agent comprising a plurality of carriers and a plurality of fibrinogen binding peptides immobilised to the carrier; a biocompatible liquid; and particles of biocompatible cross-linked polysaccharide suitable for use in haemostasis and which are insoluble in the biocompatible liquid. Such compositions may be used for the control of bleeding, especially in surgical procedures.

Provided are buffered adhesive compositions comprising a high molecular weight non-neutralized polymeric acid and a high molecular weight partially neutralized polymeric acid and products such as wound dressings and ostomy skin barriers incorporating the compositions.

Provided are buffered adhesive compositions comprising a high molecular weight non-neutralized polymeric acid and a high molecular weight partially neutralized polymeric acid and products such as wound dressings and ostomy skin barriers incorporating the compositions.

Provided herein are a biocompatible hemostatic product and a tissue sealant, including polyethylene oxide particles with a viscosity-average molecular weight ranging from 100,000 to 7,000,000 Daltons, a particle size ranging from 0.5 μm to 2000 μm and a water absorbency capacity ranging from 1 to 500 times of its own weight. Also provided herein is a method for preparing biocompatible hemostatic product and tissue sealant and the use of the biocompatible hemostatic product and tissue sealant in hemostasis, preventing adhesion, avoiding infection, promoting tissue healing, and sealing wound of tissues and organs either on animal's body surface, or inside body's cavity.

Provided are buffered adhesive compositions comprising a high molecular weight non-neutralized polymeric acid and a high molecular weight partially neutralized polymeric acid and products such as wound dressings and ostomy skin barriers incorporating the compositions.

Provided are buffered adhesive compositions comprising a high molecular weight non-neutralized polymeric acid and a high molecular weight partially neutralized polymeric acid and products such as wound dressings and ostomy skin barriers incorporating the compositions.

The invention relates to a functional wound dressing being able to provide substances supporting the healing of a wound to the wound depending on the condition of the wound. In particular, in case of an infection which is reported to be frequently associated with poorly healing wounds, such as chronic wounds, a therapeutic substance is provided to the wound whereas in other cases no therapeutic substance is provided. The present wound dressing can be used in moist wound healing and contains a substance being able to absorb wound exudate from the wound and to provide moisture to the wound.

The present invention relates to a powder type hemostatic composition and method for preparing the same, and more specifically, to powder aggregate having porosity obtained by combining powder of biocompatible hemostatic material with a binder and a method for preparing the same, and a powder type hemostatic composition which comprises the powder aggregate and shows improved hemostatic performance as compared with simple powder hemostatic agents, and can be used to a large surface area for hemostasis, or to narrow, thin or other sites to which approach for hemostasis is difficult.